Drug Research
Drug Discovery & Development

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
16-30 of 4547 results
Biogen, Alkermes to develop and commercialize ALKS 8700 to treat multiple sclerosis
Biogen and Alkermes have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate (MMF) small drug molecule in phase 3 development for the treatment of relapsing forms of multiple sclerosis (MS).
Drug Research > Drug Discovery & Development > News
MSD to establish life sciences discovery research facility in London
By PBR Staff Writer
MSD, known as Merck and co. in North America, has unveiled plans to establish a life sciences discovery research facility in London, UK, creating around 950 jobs.
Drug Research > Drug Discovery & Development > News
PhoenixBio invests in KMT Hepatech
KMT Hepatech has reached an agreement to join efforts with PhoenixBio. Together the companies will advance the use of the cDNA-uPA/SCID mouse model with highly humanized liver to support researchers across a range of drug development fields.
Drug Research > Drug Discovery & Development > News
Research finds gastric acid suppressant lansoprazole could target tuberculosis
By PBR Staff Writer
A new research in the UK suggests that a cheap and commonly used drug to treat heartburn, gastritis and ulcers has the potential to target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB).
Drug Research > Drug Discovery & Development > News
Hemogenyx, University of Oxford partner to transform blood cancers treatment
Hemogenyx Pharmaceuticals has partnered the University of Oxford to test new means of accelerating and improving the process by which transplanted blood stem cells grow and make healthy blood cells.
Drug Research > Drug Discovery & Development > News
Canadian researchers discover medication to treat amyotrophic lateral sclerosis
By PBR Staff Writer
Canadian researchers have discovered an effective medication for the treatment of individuals with amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease.
Drug Research > Drug Discovery & Development > News
Can-Fite’s former subsidiary OphthaliX merges with Wize Pharma
Can-Fite BioPharma says that its previously majority owned subsidiary OphthaliX has completed a merger with Wize Pharma.
Drug Research > Drug Discovery & Development > News
Inozyme Pharma secures $49m funding for rare disease therapies
Inozyme Pharma, which is developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, has raised a $49m Series A financing.
Drug Research > Drug Discovery & Development > News
Purdue Pharma to invest in oncology research and development
Purdue Pharma says that it has finalized major oncology related investments as part of its move to diversify its scientific research into areas of high unmet medical need.
Drug Research > Drug Discovery & Development > News
Bayer and Loxo Oncology to develop and commercialize two cancer therapies
Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.
Drug Research > Drug Discovery & Development > News
EMA grants PRIME designation for Mereo’s BPS-804 to treat osteogenesis imperfecta
Mereo BioPharma Group’s BPS-804 has been granted PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for the treatment of osteogenesis imperfecta (OI), or "brittle bone disease."
Drug Research > Drug Discovery & Development > News
Research indicates potential treatment for autism and intellectual disability
A University of Nebraska Medical Center researcher and his team at the Munroe-Meyer Institute (MMI) made a breakthrough in finding the mechanism and a possible therapeutic fix for autism and intellectual disability
Drug Research > Drug Discovery & Development > News
Sanofi to develop Principia’s MS drug candidate in $805m deal
By PBR Staff Writer
Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.
Drug Research > Drug Discovery & Development > News
Boehringer, MiNA Therapeutics partner to develop novel treatments for fibrotic liver diseases
By PBR Staff Writer
Boehringer Ingelheim has entered into collaboration and licensing agreement with MiNA Therapeutics for the development of novel treatments to treat fibrotic liver diseases.
Drug Research > Drug Discovery & Development > News
Cerenis Therapeutics acquires Lypro Biosciences
Cerenis Therapeutics has acquired Lypro Biosciences to expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery.
Drug Research > Drug Discovery & Development > News
16-30 of 4547 results